Paul A. Bunn Jr., MD, is a Distinguished Professor of Medicine and the James Dudley Endowed Professor of Lung Cancer at the University of Colorado School of Medicine. He is the principal investigator of the SPORE in Lung Cancer grant at the University of Colorado, which aims to support translational research in lung cancer. Dr. Bunn has dedicated his career to identifying novel diagnostics and treatment strategies for lung cancer and improving the outcomes of patients with lung cancer.

Paul A. Bunn Jr., MD, is a Distinguished Professor of Medicine and the James Dudley Endowed Professor of Lung Cancer at the University of Colorado School of Medicine. He is the principal investigator of the SPORE in Lung Cancer grant at the University of Colorado, which aims to support translational research in lung cancer. Dr. Bunn has dedicated his career to identifying novel diagnostics and treatment strategies for lung cancer and improving the outcomes of patients with lung cancer.

Julie R. Brahmer, MD, MSc, is the Director of the Upper Aerodigestive Cancers Program, Co-Director of the Cancer Immunology Program and Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus. Dr. Brahmer is an international leader in lung cancer clinical trials research with particular expertise in drug development for thoracic malignancies and immunotherapy. She led the first in human trial of MDX-1106, now known as nivolumab and has been a leader in the development of immunotherapy for the treatment of non-small cell lung cancer.

Dr. Jeffrey Bradley is the James W. Keller Distinguished Professor of Radiation Oncology and currently serves as the interim department chair. His clinical interest is in the management of thoracic malignancies. He serves as chair of the NRG Oncology Lung Cancer Committee and has many publications related to the therapy of lung cancer.

Dr. Penelope Bradbury is a staff medical oncologist at the Princess Margaret Cancer Centre, Toronto, Canada; Associate Professor, Department of Medicine, University of Toronto, Canada. After obtaining her medical degree from the University of Cardiff, UK and fellow of Royal Australasian College of Physicians, she undertook postgraduate fellowships at Princess Margaret Cancer Centre and the Canadian Cancer Trials Group, ON, Canada. Dr. Bradbury’s main research interest is in the field of clinical trials for thoracic cancer. Before joining the Princess Margaret Cancer Centre, she held the position of a senior investigator within the Canadian Cancer Trials Group for the thoracic and investigational new drugs program, during which time she held a Cancer Care Ontario Research Chair in Experimental Therapeutics. Dr. Bradbury is the current chair of the Canadian Cancer Trials Group Thoracic Disease Site Committee and is a recipient of the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award.

Chief of Thoracic Medical Oncology
Professor, Department of Oncology/Hematology
Co-Director, Immune Monitoring Facility
The Gloria and Edmund M. Dunn Chair in Thoracic Malignancies

Dr. Blakely is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania and trained as a clinical fellow in Medical Oncology at UCSF. His research focuses on understanding the cellular and molecular mechanisms underlying lung cancer resistance to EGFR-, and ALK-targeted therapies, and identifying new targets for molecular-directed therapies. His goal is to translate laboratory-based findings into new treatments for lung cancer patients.

I am a cell and molecular biologist and a board-certified medical oncologist. I lead a basic and translational research program focused on signal transduction and cancer genetics and the molecular basis of tumor initiation and progression. My discoveries have provided insight into the function and regulation of critical cancer-driving proteins including oncogenic receptor tyrosine kinases and RAS pathway genes. My work also uncovered drug resistance programs mediated by NF-kappaB and Hippo-YAP pathway signaling and lineage plasticity switches in lung cancer. The overall goal of my research program is to understand the regulatory principles underlying cell signaling pathways, cancer growth, and metastasis through hypothesis-driven investigations in order to improve cancer therapy and patient survival.

Dr.Andrea Bezjak is a Professor in the Departments of Radiation Oncology at the University of Toronto, Canada, thoracic radiation oncologist at the Princess Margaret Cancer Centre/ University Health Network and was the inaugural holder of the Addie MacNaughton Chair in Thoracic Radiation Oncology at the University of Toronto 2007-2019. She has authored or co-authored more than 200 peer-reviewed manuscripts and has been a principal investigator of multi-center clinical trials in lung cancer. She was the chair of the NCIC Clinical Trials Group QOL committee in the past. She has been a member of IASLC since 1995, was one of the co-Presidents of the 2018 WCLC in Toronto and is currently a member of the Board of Directors of IASLC.

Dr. Christine Bestvina is a thoracic oncologist at the University of Chicago Medicine. She received her medical degree from the University of Pennsylvania. She completed her residency at Duke University, and her fellowship training in oncology at the University of Chicago. She currently is an assistant professor at the University of Chicago in the section of Hematology/Oncology. She has published papers in several peer-reviewed journals, including Lancet Oncology and Journal of Oncology Practice.

Dr. Bestvina’s primary research interest is in the synergistic activity of immunotherapy and radiation. She is currently co-principal investigator of COSINR: Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients with Metastatic Lung Cancer. She acts as the local PI on many industry and cooperative group trials. Additionally, Dr. Bestvina has interests in translational research, working with Professor Chuan He on methylation patterns of cell free DNA in lung cancer, and the response to targeted therapies and immunotherapies